Ellipses Pharma Email Format
Biotechnology ResearchEngland, United Kingdom11-50 Employees
Ellipses Pharma is an international biotechnology company focused on advancing cancer treatments through clinical development. Headquartered in London, England, it is guided by a leadership team overseeing a growing pipeline of clinical oncology opportunities and supported by partnerships with leading academic institutions, research bodies, universities, and major pharmaceutical networks. The company relies on a Scientific Affairs Group comprising leading oncologists to oversee its approach to running multiple oncology trials in parallel. Ellipses aims to streamline the clinical trial process to reduce complexity and cost and to speed the availability of new cancer therapies to patients. Recent developments include collaboration with Kelun-Biotech on EP0031/A400 for patients outside Greater China, announced May 22, 2026, and a collaboration with Innolake Biopharm Co. Ltd to develop a first-in-class antibody-drug conjugate, announced January 19, 2026.